Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: A Target Trial Emulation.
Axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are approved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (r/r LBCL). These findings should be interpreted cautiously given differential follow-up between treatment groups and the potential for residual confounding.
Axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are approved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (r/r LBCL). These findings should be interpreted cautiously given differential follow-up between treatment groups and the potential for residual confounding.
What the study was
- Study design
- Observational cohort study
- Population
- To compare the real-world effectiveness and safety of axi-cel and liso-cel in adults with r/r LBCL using a target trial emulation.
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Transplantation and cellular therapy
Why it surfaced
Observational cohort study with abstract evidence; scored conservatively for novelty, clinical relevance, design quality, and population or unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.